Joshua J. Woods

Joshua J. Woods

Auto-generated profile, based on publicly available information

Joshua J. Woods

Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in ACS Central Science
Verified
Journal Article
Open access
JWJoshua J. Woods
Joshua J. Woods
NNNeeharika Nemani
Neeharika Nemani
SSSanthanam Shanmughapriya
Santhanam Shanmughapriya
Akshay KumarAkshay Kumar
Akshay Kumar
MZMengQi Zhang
MengQi Zhang
MMMuniswamy Madesh
Muniswamy Madesh
Mitochondrial Ca2+ (mCa2+) uptake mediated by the mitochondrial calcium uniporter (MCU) plays a critical role in signal transduction, bioenergetics, and cell death, and its dysregulation is linked to several human diseases. In this study, we report a new ruthenium complex Ru265 that is cell-permeable, minimally toxic, and highly potent with respect to MCU inhibition. Cells treated with Ru265 show inhibited MCU activity without any effect on cytosolic Ca2+ dynamics and mitochondrial membrane potential (ΔΨm). Dose-dependent studies reveal that Ru265 is more potent than the currently employed MCU inhibitor Ru360. Site-directed mutagenesis of Cys97 in the N-terminal domain of human MCU ablates the inhibitory activity of Ru265, suggesting that this matrix-residing domain is its target site. Additionally, Ru265 prevented hypoxia/reoxygenation injury and subsequent mitochondrial dysfunction, demonstrating that this new inhibitor is a valuable tool for studying the functional role of the MCU in intact biological models.

29 January 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
DADiane S. Abou
Diane S. Abou
NTNikki Thiele
Nikki Thiele
NGNicholas T. Gutsche
Nicholas T. Gutsche
AVAlexandria Villmer
Alexandria Villmer
HZHanwen Zhang
Hanwen Zhang
DTDaniel Thorek
Daniel Thorek
The therapeutic alpha-emitter 223Ra can be stably complexed in vivo, creating opportunities for the development of targeted radiopharmaceutical agents with this radionuclide.

1 April 2020 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
JWJoshua J. Woods
Joshua J. Woods
JWJustin Wilson
Justin Wilson

27 June 2019 in Inorganic Chemistry
Verified
Journal Article
Closed access
NTNikki Thiele
Nikki Thiele
JWJoshua J. Woods
Joshua J. Woods
JWJustin Wilson
Justin Wilson

3 March 2020 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
PDF file
RNRobyn J Novorolsky
Robyn J Novorolsky
MNMatthew Nichols
Matthew Nichols
JKJong S Kim
Jong S Kim
EPEvgeny V Pavlov
Evgeny V Pavlov
JWJoshua J Woods
Joshua J Woods
GRGeorge S Robertson
George S Robertson
The mitochondrial calcium (Ca2+) uniporter (MCU) mediates high-capacity mitochondrial Ca2+ uptake implicated in ischemic/reperfusion cell death. We have recently shown that inducible MCU ablation in Thy1-expressing neurons renders mice resistant to sensorimotor deficits and forebrain neuron loss in a model of hypoxic/ischemic (HI) brain injury. These findings encouraged us to compare the neuroprotective effects of Ru360 and the recently identified cell permeable MCU inhibitor Ru265. Unlike Ru360, Ru265 (2–10 µM) reached intracellular concentrations in cultured cortical neurons that preserved cell viability, blocked the protease activity of Ca2+-dependent calpains and maintained mitochondrial respiration and glycolysis after a lethal period of oxygen–glucose deprivation (OGD). Intraperitoneal (i.p.) injection of adult male C57Bl/6 mice with Ru265 (3 mg/kg) also suppressed HI-induced sensorimotor deficits and brain injury. However, higher doses of Ru265 (10 and 30 mg/kg, i.p.) produced dose-dependent increases in the frequency and duration of seizure-like behaviours. Ru265 is proposed to promote convulsions by reducing Ca2+ buffering and energy production in highly energetic interneurons that suppress brain seizure activity. These findings support the therapeutic potential of MCU inhibition in the treatment of ischemic stroke but also indicate that such clinical translation will require drug delivery strategies which mitigate the pro-convulsant effects of Ru265.

15 May 2019 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
AKA. Paden King
A. Paden King
SMSierra C. Marker
Sierra C. Marker
RSRobert V. Swanda
Robert V. Swanda
JWJoshua J. Woods
Joshua J. Woods
SQShu‐Bing Qian
Shu‐Bing Qian
JWJustin Wilson
Justin Wilson